Skip to main content

Advertisement

SpringerLink
Log in

Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

We analyzed the impact of age according to subtype and compared outcomes for breast cancer (BC) patients across two time periods to determine whether the previously observed poor prognosis associated with BC in young women persists in the context of modern adjuvant therapies and relative to BC subtypes. Women aged <50 years (y) diagnosed with invasive BC between 1986–1992 and 2004–2007 were identified from British Columbia Cancer Agency’s Breast Cancer Outcomes Database and analyzed by age category (<40 and 40–49 years) and subtype. Subtypes were defined by immunohistochemistry. Relapse-free and overall survival (RFS and OS) were estimated using the Kaplan–Meier method. Multivariable analyses using Cox regression models were performed to adjust for prognostic variables. Age <40 was associated with inferior 5y-RFS for Luminal cases within both time cohorts (1986–1992: 65 vs. 77 %, P = 0.009, 2004–2007: 79 vs. 92 %, P = < 0.001). Inferior 5y-RFS was observed for those <40 with HER2-positive cancers in the 1986–1992, but not 2004–2007 cohort (49 vs. 66 %, P = 0.017, and 89 vs. 89 %, P = 0.879). No difference according to age was observed for triple-negative cancers in either time cohort (1986–1992: 60 vs. 63 %, P = 0.868, 2004–2007: 78 vs. 77 %, P = 0.933). 5y-RFS improved over time for all subgroups. OS for the Luminal subgroup improved for those 40–49 years but not <40 years. The effect of age varies with subtype. Age <40 years predicts inferior RFS and OS for Luminal BC in the modern era. Research efforts should target Luminal BC in young women for whom discrepancies in outcome persist.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. El Saghir NS, Seoud M, Khalil MK et al (2006) Effects of young age at presentation on survival in breast cancer. BMC Cancer 6:194. doi:10.1186/1471-2407-6-194

    Article  PubMed  PubMed Central  Google Scholar 

  2. de la Rochefordiere A, Asselain B, Campana F et al (1993) Age as prognostic factor in premenopausal breast carcinoma. Lancet 341:1039–1043

    Article  PubMed  Google Scholar 

  3. Bharat A, Aft RL, Gao F et al (2009) Patient and tumor characteristics associated with increased mortality in young women (<or = 40 years) with breast cancer. J Surg Oncol 100:248–251. doi:10.1002/jso.21268;10.1002/jso.21268

    Article  PubMed  Google Scholar 

  4. Anders CK, Johnson R, Litton J et al (2009) Breast cancer before age 40 years. Semin Oncol 36:237–249. doi:10.1053/j.seminoncol.2009.03.001;10.1053/j.seminoncol.2009.03.001

    Article  PubMed  PubMed Central  Google Scholar 

  5. Anders CK, Fan C, Parker JS et al (2011) Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol 29:e18–20. doi:10.1200/JCO.2010.28.9199;10.1200/JCO.2010.28.9199

    Article  PubMed  PubMed Central  Google Scholar 

  6. Collins LC, Marotti JD, Gelber S et al (2012) Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat 131:1061–1066. doi:10.1007/s10549-011-1872-9;10.1007/s10549-011-1872-9

    Article  PubMed  CAS  Google Scholar 

  7. Colleoni M, Rotmensz N, Peruzzotti G et al (2006) Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol 17:1497–1503. doi:10.1093/annonc/mdl145

    Article  PubMed  CAS  Google Scholar 

  8. Smith BD, Jiang J, McLaughlin SS et al (2011) Improvement in breast cancer outcomes over time: are older women missing out? J Clin Oncol 29:4647–4653. doi:10.1200/JCO.2011.35.8408

    Article  PubMed  Google Scholar 

  9. Brenner H, Francisci S, de Angelis R et al (2009) Long-term survival expectations of cancer patients in Europe in 2000–2002. Eur J Cancer 45:1028–1041. doi:10.1016/j.ejca.2008.11.005

    Article  PubMed  Google Scholar 

  10. Verdecchia A, Guzzinati S, Francisci S et al (2009) Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 45:1042–1066. doi:10.1016/j.ejca.2008.11.029

    Article  PubMed  Google Scholar 

  11. Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792

    Article  PubMed  CAS  Google Scholar 

  12. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717. doi:10.1016/S0140-6736(05)66544-0

    Article  Google Scholar 

  13. Bria E, Nistico C, Cuppone F et al (2006) Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 106:2337–2344. doi:10.1002/cncr.21886

    Article  PubMed  CAS  Google Scholar 

  14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672

    Article  PubMed  CAS  Google Scholar 

  15. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502. doi:10.1001/jama.295.21.2492

    Article  PubMed  CAS  Google Scholar 

  16. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874. doi:10.1073/pnas.191367098

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423. doi:10.1073/pnas.0932692100

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Cancello G, Maisonneuve P, Rotmensz N et al (2010) Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol 21:1974–1981. doi:10.1093/annonc/mdq072;10.1093/annonc/mdq072

    Article  PubMed  CAS  Google Scholar 

  19. Anders CK, Hsu DS, Broadwater G et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330. doi:10.1200/JCO.2007.14.2471;10.1200/JCO.2007.14.2471

    Article  PubMed  Google Scholar 

  20. Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728. doi:10.1002/cncr.22618

    Article  PubMed  Google Scholar 

  21. Morrison DH, Rahardja D, King E et al (2012) Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer. Br J Cancer 107:382–387. doi:10.1038/bjc.2012.219;10.1038/bjc.2012.219

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  22. Aebi S, Gelber S, Castiglione-Gertsch M et al (2000) Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355:1869–1874

    Article  PubMed  CAS  Google Scholar 

  23. Goldhirsch A, Gelber RD, Yothers G et al (2001) Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 30:44–51

    Article  PubMed  Google Scholar 

  24. Kim EK, Noh WC, Han W et al (2011) Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study. World J Surg 35:1244–1253. doi:10.1007/s00268-011-1071-1;10.1007/s00268-011-1071-1

    Article  PubMed  Google Scholar 

  25. Ahn SH, Son BH, Kim SW et al (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea—a report from the Korean Breast Cancer Society. J Clin Oncol 25:2360–2368. doi:10.1200/JCO.2006.10.3754

    Article  PubMed  Google Scholar 

  26. Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376. doi:10.1158/1078-0432.CCR-07-1658;10.1158/1078-0432.CCR-07-1658

    Article  PubMed  CAS  Google Scholar 

  27. Partridge AH, Wang PS, Winer EP et al (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602–606

    Article  PubMed  CAS  Google Scholar 

  28. Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120–4128. doi:10.1200/JCO.2009.25.9655;10.1200/JCO.2009.25.9655

    Article  PubMed  PubMed Central  Google Scholar 

  29. Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529–537. doi:10.1007/s10549-010-1132-4

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  30. Swain SM, Jeong JH, Geyer CE Jr et al (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053–2065. doi:10.1056/NEJMoa0909638;10.1056/NEJMoa0909638

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  31. Parulekar WR, Day AG, Ottaway JA et al (2005) Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study–NCIC CTG MA.5. J Clin Oncol 23:6002–6008

    Article  PubMed  Google Scholar 

  32. Pagani O, O’Neill A, Castiglione M et al (1998) Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34:632–640

    Article  PubMed  CAS  Google Scholar 

  33. Petrek JA, Naughton MJ, Case LD et al (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24:1045–1051

    Article  PubMed  Google Scholar 

  34. Walshe JM, Denduluri N, Swain SM (2006) Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24:5769–5779

    Article  PubMed  CAS  Google Scholar 

  35. Pagani O, Regan MM, Walley BA et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. doi:10.1056/NEJMoa1404037

    PubMed  Google Scholar 

  36. Berger NA (2014) Obesity and cancer pathogenesis. Ann N Y Acad Sci 1311:57–76. doi:10.1111/nyas.12416

    Article  PubMed  CAS  Google Scholar 

  37. Pan H, Gray, Richard G on behalf of the Early Breast Cancer Trialists’ Collaborative Group (2014) Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials. JCO 32:abstract 503

  38. Partridge AH, Gelber S, Piccart-Gebhart MJ et al (2013) Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol 31:2692–2698. doi:10.1200/JCO.2012.44.1956;10.1200/JCO.2012.44.1956

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. BC Cancer Agency, Vancouver Cancer Centre, University of British Columbia, 600 W 10th Avenue, Vancouver, BC, V5Z 4E6, Canada

    Wilson Sheridan, Tyldesley Scott, Speers Caroline, Zheng Yvonne, Voduc David, Gelmon Karen & Chia Stephen

  2. BC Cancer Agency, Vancouver Island Cancer Centre, University of British Columbia, 2410 Lee Avenue, Victoria, BC, V8R 6V5, Canada

    Bernstein Vanessa

Authors
  1. Wilson Sheridan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tyldesley Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Speers Caroline
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zheng Yvonne
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bernstein Vanessa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Voduc David
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gelmon Karen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chia Stephen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wilson Sheridan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sheridan, W., Scott, T., Caroline, S. et al. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?. Breast Cancer Res Treat 147, 617–629 (2014). https://doi.org/10.1007/s10549-014-3125-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-014-3125-1

Keywords

Search

Navigation